Fortress Biotech subsidiary Caelum Biosciences enters biopharmaceutical manufacturing agreement with Patheon

Published: 2-Jun-2017
Regulatory Research & Development

Agreement will support Phase II/III studies of Caelum's CAEL-101 in AL amyloidosis

Fortress Biotech, Inc., a biopharmaceutical company dedicated to acquiring, developing and commercialising novel pharmaceutical and biotechnology products, has announced that its subsidiary Caelum Biosciences has entered a biopharmaceutical manufacturing agreement with Patheon NV for process development and current good manufacturing practices (cGMP) production of Caelum's lead therapy CAEL-101.

The agreement will support Phase II/III studies of CAEL-101 for the treatment of amyloid light chain (AL) amyloidosis, a rare systemic disorder that leads to the build-up of amyloid proteins in and around tissues, nerves and organs, resulting in organ damage and high mortality rates.

CAEL-101 is currently being evaluated by study sponsor Columbia University in a Phase Ib study in AL amyloidosis.

Michael Spector, Chief Executive Officer of Caelum, said: "We believe this manufacturing agreement with Patheon will enable continued progression of the CAEL-101 clinical development programme. The establishment of this important collaboration, now allows us to plan for our Phase II/III programme."

Patheon provides end-to-end, fully integrated services for both drug substances and drug products to help clients accelerate development in the rapidly evolving world of biologics.

  • Companies:
  • Patheon
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Inside Patheon’s new flexible pharmaceutical development facilities

Read more
In the pharmaceutical sector, flexible facilities are in demand as new niche therapies replace traditional blockbusters. Patheon’s Tony Pidgeon, Process Technology Director, and Louise Hall, PMP, Senior Director, Pharmaceutical Development Services, describe improvements made at the company’s new sterile PDS Suite at its Greenville (NC, USA) site to meet the new trend

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  4. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  5. Thermo Fisher Scientific officially opens US oral solid dose testing and R&D facility The company's further expansion in the Bend, Oregon area will assist its pharmaceutical clients in the early development of oral solid dosage (OSD) forms

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Inside Patheon’s new flexible pharmaceutical development facilities

In the pharmaceutical sector, flexible facilities are in demand as new niche therapies replace traditional blockbusters. Patheon’s Tony Pidgeon, Process Technology Director, and Louise Hall, PMP, Senior Director, Pharmaceutical Development Services, describe improvements made at the company’s new sterile PDS Suite at its Greenville (NC, USA) site to meet the new trend
Manufacturing

Thermo Fisher Scientific to acquire leading CDMO, Patheon

The transaction represents a purchase price of approximately $7.2bn
Regulatory

Patheon outsources most NDAs of any provider

Company held approximately 30% of all outsourced approvals in 2016, four times more than the nearest competitor
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Now is the time to outsource the management of outsourcing

More than ever before, specialist expertise is being called upon by the pharma industry – from strategy, supply chain and regulatory boutiques through to one-stop CDMOs that provide the whole spectrum of API development to final product production. Susan Birks talked to Patheon about the trends
Manufacturing

Patheon agrees biologics deal with Inhibrx

Initial development work will focus on establishing platform processes for Inhibrx’s cell lines
Research & Development

Patheon expands stability testing capabilities

Company invests US$3m in equipment and talent in its centralised stability testing lab
Manufacturing

Patheon to participate in industry panels at Interphex

Patheon will showcase Patheon OneSource, the industry-leading solution that provides a simplified and customised offering, including both drug substance and drug production services to help clients get to market faster and cost effectively
Subscribe now